ライフサイエンスコーパス: romosozumab

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 oice response system to receive subcutaneous romosozumab (210 mg once monthly) or subcutaneous teripa

2 a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg)

3 y nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups.

4 We compared the effects of 12 months of romosozumab (AMG 785), a sclerostin monoclonal antibody,

5 events were reported in 17 (8%) patients on romosozumab and in 23 (11%) on teriparatide; none were j

6 The monoclonal antibody romosozumab binds to sclerostin and increases bone forma

7 real BMD was 2.6% (95% CI 2.2 to 3.0) in the romosozumab group and -0.6% (-1.0 to -0.2) in the teripa

8 206 patients in the romosozumab group and 209 in the teriparatide group were

9 There were six (3%) patients in the romosozumab group compared with 12 (6%) in the teriparat

10 were nasopharyngitis (28 [13%] of 218 in the romosozumab group vs 22 [10%] of 214 in the teriparatide

11 Romosozumab is a monoclonal antibody that binds to and i

12 In such patients, romosozumab led to gains in hip BMD that were not observ

13 re randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210

14 2014, 436 patients were randomly assigned to romosozumab (n=218) or teriparatide (n=218).

15 s from patients with rare bone diseases (eg, romosozumab, odanacatib).

16 udy, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal

17 te group, representing a 27% lower risk with romosozumab (P<0.001).

18 adverse events were observed more often with romosozumab than with alendronate (50 of 2040 patients [

19 steonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronat

20 new vertebral fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 pati

21 nvertebral fractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate

22 curred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 pati

23 oporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendron

24 Romosozumab was also associated with large increases in

25 In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral d

26 All dose levels of romosozumab were associated with significant increases i

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。